Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGRX
Previous Symbol
CUSIPN/A
Phone609-683-1880
Debt
Debt-to-Equity RatioN/A
Current Ratio2.10
Quick Ratio2.10
Price-To-Earnings
Trailing P/E Ratio-0.92
Forward P/E Ratio-1.40
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.67 per share
Price / Book1.25
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-28,300,000.00
Net MarginsN/A
Return on Equity-78.04%
Return on Assets-56.15%
Miscellaneous
Employees21
Outstanding Shares34,380,000
Market Cap$31.29 million
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) issued its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
6 brokers have issued 12-month target prices for Agile Therapeutics' stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Agile Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
Has Agile Therapeutics been receiving favorable news coverage?
Media coverage about AGRX stock has been trending positive recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agile Therapeutics earned a news impact score of 3.0 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the company's share price in the next several days.
Are investors shorting Agile Therapeutics?
Agile Therapeutics saw a increase in short interest in October. As of October 31st, there was short interest totalling 2,529,877 shares, an increase of 124.2% from the October 15th total of 1,128,282 shares. Based on an average daily volume of 4,351,706 shares, the short-interest ratio is presently 0.6 days. Approximately 10.6% of the company's shares are sold short. View Agile Therapeutics' Current Options Chain.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include Mustang Bio (MBIO), Adamis Pharmaceuticals (ADMP), Cue Biopharma (CUE), VBI Vaccines (VBIV), Sierra Oncology (SRRA), Selecta Biosciences (SELB), XOMA (XOMA), Ovid Therapeutics (OVID), PhaseBio Pharmaceuticals (PHAS), Chembio Diagnostics (CEMI), Processa Pharmaceuticals (PCSA), MOTIF BIO PLC/S (MTFB), Correvio Pharma (CORV), Tetraphase Pharmaceuticals (TTPH) and Northwest Biotherapeutics (NWBO).
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 59)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 50)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 61)
Who are Agile Therapeutics' major shareholders?
Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.56%) and Fosun International Ltd (1.36%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Life Sciences Maste Perceptive and Renee Selman. View Institutional Ownership Trends for Agile Therapeutics.
Which institutional investors are buying Agile Therapeutics stock?
AGRX stock was bought by a variety of institutional investors in the last quarter, including Fosun International Ltd and Renaissance Technologies LLC. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Renee Selman. View Insider Buying and Selling for Agile Therapeutics.
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $0.84.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $31.29 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe.
What is Agile Therapeutics' official website?
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
